McKesson Corporation vs Riot Platforms Inc — how do they compare? McKesson Corporation trades at $878 (market cap $105.14B), while Riot Platforms Inc trades at $20.25 (market cap $7.59B). The key difference: McKesson Corporation is far larger — about 13.9× Riot Platforms Inc's market cap, and McKesson Corporation pays a 0.42% dividend while Riot Platforms Inc pays none. Which is the better fit depends on your goals.
| MCK | RIOT | |
|---|---|---|
Market Cap | $105.14B | $7.59B |
Sector | Health | Technology |
52-Week High | $995.69 | $28.67 |
52-Week Low | $659.01 | $11.33 |
Enterprise Value | $111.67B | $8.00B |
Dividend Yield | 0.42% | — |
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $877.87, down 0.23% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company reported robust Q1 2027 results with EPS of $9.93 beating estimates by 20% year-over-year, driven by specialty drug growth and oncology performance. Revenue reached $105.4 billion, up 8%, prompting management to raise full-year adjusted EPS guidance. Analyst consensus remains strongly bullish with 24 buy ratings and a $990.67 price target, representing 13% upside potential.
MCK presents a compelling investment case with consistent earnings beats, raised guidance, and strong operational cash flow of $6.9 billion projected for 2026. Key risks include margin pressure from the low 1.12% net income margin, high accounts payable of $55.33 billion, and negative shareholder equity of -$2.07 billion. The stock's valuation at 24.19 P/E appears reasonable given growth prospects, but investors should monitor debt levels and pharmaceutical pricing dynamics.
RIOT Platforms trades at $20.32, up 4.74% today, amid strong technical resistance near $21-$23 levels. The stock shows bearish momentum despite recent positive news about a $9.1 billion AI infrastructure deal with Anthropic. Fundamentally, the company continues to post significant losses with a -196.28% net income margin, though revenue growth remains steady at $675 million projected for 2026.
While analyst consensus remains overwhelmingly bullish with a $33.40 price target, investors face substantial execution risks as RIOT transitions from bitcoin mining to AI infrastructure. The company's persistent negative cash flow and high valuation multiples present challenges despite the transformative potential of the Anthropic partnership.
Trailing returns across standard periods
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →